Clinical trial

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

NCT05758831

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-06-01

PhasePHASE3

Study timeline

Study start (actual)2023-06-01Date precision: day

Registry last updated2026-02-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Relapsing-remitting Multiple Sclerosisunresolved

Interventions

Perfusion of treatment RituximabDRUG

Perfusion of treatment OcrelizumabDRUG

Sponsors & collaborators

Rennes University Hospitallead sponsor

Mapped research locations

ParisFrance2 ToulouseFrance1 MarseilleFrance1 MontpellierFrance1 StrasbourgFrance1 LilleFrance1 NantesFrance1 RennesFrance1 NiceFrance1 CaenFrance1 Clermont-FerrandFrance1 RouenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05758831 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.